Bruce E Pollock1, Michael J Link2, Scott L Stafford3, Ian F Parney4, Yolanda I Garces3, Robert L Foote3. 1. Department of Neurological Surgery, Mayo Clinic College of Medicine, Rochester, Minnesota; Department of Radiation Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota. Electronic address: pollock.bruce@mayo.edu. 2. Department of Neurological Surgery, Mayo Clinic College of Medicine, Rochester, Minnesota; Department of Otorhinolaryngology, Mayo Clinic College of Medicine, Rochester, Minnesota. 3. Department of Radiation Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota. 4. Department of Neurological Surgery, Mayo Clinic College of Medicine, Rochester, Minnesota.
Abstract
PURPOSE: To determine the risk of radiation-induced tumors or malignant transformation after single-fraction intracranial stereotactic radiosurgery (SRS). METHODS AND MATERIALS: We performed a retrospective review of 1837 patients who received single-fraction SRS for arteriovenous malformation or benign tumor (meningioma, vestibular schwannoma, pituitary adenoma, glomus tumor) at a single center between 1990 and 2009. Patients were excluded if they refused research authorization (n=31), had a genetic predisposition to tumor development (n=84), received prior or concurrent radiation therapy (n=79), or had less than 5 years of imaging follow-up after SRS (n=501). The median imaging follow-up period for the remaining 1142 patients was 9.0 years (range, 5-24.9 years). RESULTS: No radiation-induced tumors were identified in 11,264 patient-years of follow-up after SRS. The risk of a radiation-induced tumor developing after SRS was 0.0% at 5 years (95% confidence interval [CI], 0.0%-0.4%), 0.0% at 10 years (95% CI, 0.0%-0.9%), and 0.0% at 15 years (95% CI, 0.0%-2.8%). Malignant transformation occurred in 7 of 316 meningioma patients (2.2%) and 1 of 358 vestibular schwannoma patients (0.3%) at a median of 4.9 years (range, 2.8-13.8 years) after SRS. No cases of malignant transformation were noted in patients with pituitary adenomas (n=188) or glomus tumors (n=47). The 5-, 10-, and 15-year risk of malignant transformation was 0.5% (95% CI, 0.0%-0.9%), 0.8% (95% CI, 0.0%-1.8%), and 2.4% (95% CI, 0.0%-5.5%), respectively. Patients who underwent prior resection (hazard ratio, 14.56; 95% CI, 1.79-118.33; P=.01) and who had meningioma pathology (hazard ratio, 11.72; 95% CI, 1.44-96.15; P=.02) were at increased risk of malignant transformation. CONCLUSIONS: The risk of radiation-induced tumors or malignant transformation after SRS is very low and should not be used as a justification for choosing alternative treatment approaches (surgical resection, observation) over SRS for appropriate patients.
PURPOSE: To determine the risk of radiation-induced tumors or malignant transformation after single-fraction intracranial stereotactic radiosurgery (SRS). METHODS AND MATERIALS: We performed a retrospective review of 1837 patients who received single-fraction SRS for arteriovenous malformation or benign tumor (meningioma, vestibular schwannoma, pituitary adenoma, glomus tumor) at a single center between 1990 and 2009. Patients were excluded if they refused research authorization (n=31), had a genetic predisposition to tumor development (n=84), received prior or concurrent radiation therapy (n=79), or had less than 5 years of imaging follow-up after SRS (n=501). The median imaging follow-up period for the remaining 1142 patients was 9.0 years (range, 5-24.9 years). RESULTS: No radiation-induced tumors were identified in 11,264 patient-years of follow-up after SRS. The risk of a radiation-induced tumor developing after SRS was 0.0% at 5 years (95% confidence interval [CI], 0.0%-0.4%), 0.0% at 10 years (95% CI, 0.0%-0.9%), and 0.0% at 15 years (95% CI, 0.0%-2.8%). Malignant transformation occurred in 7 of 316 meningiomapatients (2.2%) and 1 of 358 vestibular schwannomapatients (0.3%) at a median of 4.9 years (range, 2.8-13.8 years) after SRS. No cases of malignant transformation were noted in patients with pituitary adenomas (n=188) or glomus tumors (n=47). The 5-, 10-, and 15-year risk of malignant transformation was 0.5% (95% CI, 0.0%-0.9%), 0.8% (95% CI, 0.0%-1.8%), and 2.4% (95% CI, 0.0%-5.5%), respectively. Patients who underwent prior resection (hazard ratio, 14.56; 95% CI, 1.79-118.33; P=.01) and who had meningioma pathology (hazard ratio, 11.72; 95% CI, 1.44-96.15; P=.02) were at increased risk of malignant transformation. CONCLUSIONS: The risk of radiation-induced tumors or malignant transformation after SRS is very low and should not be used as a justification for choosing alternative treatment approaches (surgical resection, observation) over SRS for appropriate patients.
Authors: Lucas P Carlstrom; Amanda Muñoz-Casabella; Avital Perry; Christopher S Graffeo; Michael J Link Journal: Otol Neurotol Date: 2021-12-01 Impact factor: 2.619
Authors: Alexander D Sherry; Brian Bingham; Ellen Kim; Meredith Monsour; Guozhen Luo; Albert Attia; Lola B Chambless; Anthony J Cmelak Journal: J Radiosurg SBRT Date: 2020
Authors: Roland Goldbrunner; Michael Weller; Jean Regis; Morten Lund-Johansen; Pantelis Stavrinou; David Reuss; D Gareth Evans; Florence Lefranc; Kita Sallabanda; Andrea Falini; Patrick Axon; Olivier Sterkers; Laura Fariselli; Wolfgang Wick; Joerg-Christian Tonn Journal: Neuro Oncol Date: 2020-01-11 Impact factor: 12.300
Authors: M Elise Graham; Brian D Westerberg; Jane Lea; Paul Hong; Simon Walling; David P Morris; Andrea L O Hebb; Rochelle Galleto; Emily Papsin; Maeve Mulroy; Hannah Foggin; Manohar Bance Journal: J Otolaryngol Head Neck Surg Date: 2018-09-03
Authors: Sara Alatriste-Martínez; Sergio Moreno-Jiménez; Guillermo A Gutiérrez-Aceves; José de Jesús Suárez-Campos; Olivia Amanda García-Garduño; Alejandro Rosas-Cabral; Miguel Ángel Celis-López Journal: World Neurosurg X Date: 2019-03-07
Authors: William C Chen; Harish N Vasudevan; Abrar Choudhury; Melike Pekmezci; Calixto-Hope G Lucas; Joanna Phillips; Stephen T Magill; Matthew S Susko; Steve E Braunstein; Nancy Ann Oberheim Bush; Lauren Boreta; Jean L Nakamura; Javier E Villanueva-Meyer; Penny K Sneed; Arie Perry; Michael W McDermott; David A Solomon; Philip V Theodosopoulos; David R Raleigh Journal: Neurosurgery Date: 2020-12-15 Impact factor: 5.315
Authors: Karol P Budohoski; James Clerkin; Christopher P Millward; Philip J O'Halloran; Mueez Waqar; Seamus Looby; Adam M H Young; Mathew R Guilfoyle; Diana Fitzroll; Abel Devadass; Kieren Allinson; Michael Farrell; Mohsen Javadpour; Michael D Jenkinson; Thomas Santarius; Ramez W Kirollos Journal: Acta Neurochir (Wien) Date: 2018-06-30 Impact factor: 2.216